Genetic profiling involves analyzing a patient's DNA to identify mutations that drive cancer growth. Techniques like Next-Generation Sequencing (NGS) allow for comprehensive analysis, helping to identify actionable targets for therapy. For example, patients with BRCA1 or BRCA2 mutations may benefit from PARP inhibitors, while those with EGFR mutations might respond well to tyrosine kinase inhibitors.
